Immuno Cellular Therapeutics
Biotechnology, Calabasas, California, 91362, United States, 1-10 Employees
Phone Number: +18*********
Who is IMMUNOCELLULAR THERAPEUTICS
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has ...
Read More
-
Headquarters: Calabasas, California, 91362, United States
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 541711 |
Show More
Does something look wrong? Fix it. | View contact records from IMMUNOCELLULAR THERAPEUTICS
ImmunoCellular Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ImmunoCellular Therapeutics
Answer: ImmunoCellular Therapeutics's headquarters are located at Calabasas, California, 91362, United States
Answer: ImmunoCellular Therapeutics's phone number is +18*********
Answer: ImmunoCellular Therapeutics's official website is https://imuc.com
Answer: ImmunoCellular Therapeutics's revenue is $5 Million to $10 Million
Answer: ImmunoCellular Therapeutics's SIC: 2834
Answer: ImmunoCellular Therapeutics's NAICS: 541711
Answer: ImmunoCellular Therapeutics has 1-10 employees
Answer: ImmunoCellular Therapeutics is in Biotechnology
Answer: ImmunoCellular Therapeutics contact info: Phone number: +18********* Website: https://imuc.com
Answer: ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellulars pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patients hematopoietic stem cells to generate antigen-specific cancer-killing T-cells.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month